NEWSROOM
Press Releases by Agendia
News
Press Releases
MammaPrintยฎ Approved for Reimbursement in Germany
IRVINE, Calif.,ย Oct. 21, 2020ย /PRNewswire/ --ย Agendia Inc., a world leader in precision oncology for breast cancer, announced today that the Federal Joint Committee (G-BA) has approved MammaPrintยฎ , Agendia's 70-Gene Breast Cancer Recurrence Assay. The G-BA Read More
Agendia to Participate in Stifel 2020 Virtual Healthcare Conference
Irvine, Calif., October 15, 2020 โ Agendia, Inc., a world leader in precision oncology for breast cancer, today announced its participation in the 2020 Stifel Virtual Healthcare Conference, which takes place November 16-18, 2020. Agendia Read More
Agendia, HiSS Diagnostics and PathoNext offer local MammaPrint and BluePrint testing for breast cancer patients in Germany
IRVINE, CALIF., U.S โ 6 October 2020 โ Agendia Inc., a world leader in precision oncology for breast cancer, announced today the availability of local testing for its CE-marked MammaPrintยฎ BluePrintยฎ Breast Cancer Recurrence and Read More
Agendia Celebrates Breast Cancer Awareness Month with Digital Art Installation
I AM HERE: An Intimate Portrait Series launches today Irvine, Calif., October 1, 2020 โ In celebration of Breast Cancer Awareness Month, Agendia, Inc., a world leader in precision oncology for breast cancer, is proud Read More
Agendia Presents New Data Demonstrating MammaPrintโs Clinical Utility in Treatment Decisions for Ultra-Low Risk Breast Cancer Patients at the European Society for Medical Oncology Virtual Congress
Irvine, California โ September 17, 2020 โ Agendia, Inc., a world leader in precision oncology for breast cancer, today presented data at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 showing that MammaPrintโs Read More
Agendia to Showcase New Data at the European Society for Medical Oncology Virtual Congress 2020
IRVINE, Calif.,ย Sept. 14, 2020ย /CNW/ -ย Agendia, Inc. a world leader in precision oncology for breast cancer today announced that new clinical data from its ongoing research in breast cancer is to be presented at the upcomingย European Read More
MINDACT Study Shows MammaPrintยฎ Provides Widespread Health System Cost Savings
Analysis Published in European Journal of Cancer Use of MammaPrint genomic assay alongside clinical assessment is cost-effective versus clinical assessment alone IRVINE, Calif.,ย Aug. 25, 2020 -ย Agendia, Inc., a world leader in precision oncology for breast Read More